Lyka Labs (LYKALABS)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Lyka Labs is exactly the kind of stock that makes me pause. A pharmaceutical company selling at ₹59.21 with a market cap of ₹223 crore, yet it earns nothing. The P/E is meaningless at 0.00 because profits have disappeared. Over the latest quarter, sales were ₹31 crore and net profit was roughly zero. Over the year, sales fell 9.08% and profit growth collapsed by 100%. This is not a business with visible earning power; it is a business in distress or transition. The balance sheet shows a book value of ₹37.13, so at ₹59.21 I am paying 1.59 times book for a company that returns -0.94% on equity. That fails my test of buying decent businesses at fair prices. The Piotroski score of 3 out of 9 confirms weak financial health. On the positive side, return on capital employed is 9.91%, which is better than the negative ROE and suggests some underlying asset productivity. Promoter holding is high at 58.16%, which aligns interests, but ownership alone cannot justify a premium valuation. There is no dividend to compensate me while I wait. The 52-week range of ₹44.10 to ₹102.99 shows how volatile and speculative this stock has been. I would need a clear path to sustained profitability, evidence that sales decline has reversed, and a margin of safety below book value or at least near it before I show any interest. This is a possible turnaround situation, but the turn has not yet appeared in the numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer